KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Capital Expenditures (2020 - 2025)

Recursion Pharmaceuticals' Capital Expenditures history spans 6 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 110.4% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $6.5 million, up 1373.58%, while the annual FY2025 figure was $6.5 million, 1373.58% up from the prior year.
  • Capital Expenditures reached $1.2 million in Q4 2025 per RXRX's latest filing, down from $5.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $34.0 million in Q4 2022 to a low of -$12.0 million in Q4 2024.
  • Average Capital Expenditures over 5 years is $3.2 million, with a median of $1.2 million recorded in 2025.
  • Peak YoY movement for Capital Expenditures: skyrocketed 2676.62% in 2023, then crashed 678.52% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $7.3 million in 2021, then soared by 363.0% to $34.0 million in 2022, then crashed by 93.91% to $2.1 million in 2023, then plummeted by 678.52% to -$12.0 million in 2024, then surged by 110.4% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Capital Expenditures are $1.2 million (Q4 2025), $5.0 million (Q3 2025), and -$883000.0 (Q2 2025).